Pitolisant and Cariprazine: Interaction Details
AI-assisted, pharmacist-reviewed · AI content regenerated Jul 16, 2026 · Source data updated Jul 16, 2026 · Sources: FDA labeling, DDInter 2.0, cited literature
Cariprazine
Pitolisant
How we grade severity & evidence
Severity levels
- Contraindicated: These should generally not be used together.
- Major: Potentially serious — often needs a change or close monitoring.
- Moderate: Can be significant — usually manageable with monitoring.
- Minor: Usually limited clinical impact.
Evidence grades
- Established: Well documented — supported by controlled studies or strong clinical data.
- Probable: Good supporting evidence, though not definitively proven.
- Suspected: Some evidence suggests this interaction, but it is not well established.
- Possible: Limited or conflicting evidence; the interaction may occur.
- Theoretical: Predicted from the drugs' pharmacology; not yet confirmed in people.
Ratings come from the documented interaction literature and are reviewed by a pharmacist. They describe the documented risk of the combination, not what will necessarily happen to you — your dose, timing, and health picture all matter.
These two medicines can affect each other. Cariprazine (Vraylar) is broken down in your body by a liver enzyme called CYP3A4. Pitolisant (Wakix) can speed up that enzyme. Here is the tricky part: this same enzyme both creates and clears cariprazine's active forms, so speeding it up could push the levels either up or down. Because of that, the combined effect on cariprazine hasn't been well studied and is hard to predict.
The good news is this is a known concern, and your care team can manage it. Keep taking both exactly as prescribed and check with your doctor or pharmacist before making any changes.
Mechanism: Pitolisant is a moderate CYP3A4 inducer; cariprazine is a CYP3A4 substrate. Notably, CYP3A4 governs both formation and elimination of cariprazine's active metabolites (desmethyl- and didesmethyl-cariprazine), so the net effect of induction on active-moiety exposure is unpredictable.
- Direction: unclear (could reduce or alter active metabolite exposure).
- Onset: unspecified; enzyme induction is typically delayed (days to weeks).
- Evidence: theoretical; not formally studied.
- Severity: major, combination not recommended.
Management: Avoid coadministration where possible. If used together, individualize dosing and monitor closely for loss of efficacy or altered tolerability of cariprazine.
What happens
Effects on the cariprazine exposure has not been evaluated and the net effect is unclear
Interaction Deep Dive
It is advised against giving cariprazine (a substrate of CYP3A4) together with a CYP3A4 inducer. The enzyme CYP3A4 handles both the generation and clearance of cariprazine's active metabolites. How CYP3A4 inducers influence cariprazine exposure has not been studied, and the overall effect remains uncertain1.
Why it happens (mechanism)
Induction of CYP3A4-mediated metabolism of cariprazine
How to manage this interaction
This combination is generally not recommended, but if your prescriber has chosen it, here is how a care team typically handles it:
- Keep taking both exactly as prescribed unless your doctor tells you otherwise.
- Your cariprazine dose may need to be adjusted and individualized by your care team.
- Your team may monitor you more closely for any change in how well your cariprazine is working or how you feel.
Tell your pharmacist or prescriber if you notice returning symptoms, new side effects, or anything unusual so they can tailor your treatment.
Management is individual — confirm any change with your pharmacist or prescriber.
Common questions
Can I take Pitolisant and Cariprazine together?
Pitolisant may speed up the breakdown of cariprazine, and the net result is unpredictable, so this pairing is generally not recommended. Do not change anything on your own; talk with your prescriber or pharmacist about the best plan. Always confirm with your pharmacist or prescriber before making any change.
How serious is the Pitolisant and Cariprazine interaction?
It is rated major. Potentially serious — often needs a change or close monitoring.
How quickly could this interaction happen?
The documented onset is "unspecified". The timing of this interaction is not well characterized.
How is the Pitolisant and Cariprazine interaction managed?
This combination is generally not recommended, but if your prescriber has chosen it, here is how a care team typically handles it: Keep taking both exactly as prescribed unless your doctor tells you otherwise. Your cariprazine dose may need to be adjusted and individualized by your care team. Your team may monitor you more closely for any change in how well your cariprazine is working or how you f… Management is individual — always follow your own care team's guidance.
How strong is the evidence for this interaction?
The evidence is graded "theoretical". Predicted from the drugs' pharmacology; not yet confirmed in people.
Questions for your pharmacist
- Does my dose of Pitolisant or Cariprazine need adjusting while I take them together?
- What symptoms should prompt me to call you or my prescriber right away?
- Does the timing of my doses matter for this combination?
- Is there a safer alternative to one of these medications for me?
References (1)
- Product Information: VRAYLAR(R) oral capsules, cariprazine oral capsules. AbbVie Inc. (per FDA), North Chicago, IL, 2024. DailyMed
Keep reading about Cariprazine
Keep reading about Pitolisant
Check another combination
Our instant two-drug interaction checker is almost here.
Still have questions about this combination?
Every question gets a real answer from a licensed pharmacist — free, and usually within a day.
Ask the pharmacist